Literature DB >> 3180405

Surgical management of doubly committed subarterial ventricular septal defects.

M R de Leval1, M Pozzi, V Starnes, I D Sullivan, J Stark, J Somerville, R H Anderson, J E Deanfield.   

Abstract

The clinical presentation, diagnosis, and surgical treatment of 63 patients with doubly committed subarterial ventricular septal defects (DCVSD) were analyzed retrospectively. The patients were divided into three groups. Thirty-one patients had severe congestive heart failure in infancy and presently have a large ventricular septal defect that has no tendency to close or to produce aortic valve regurgitation (Group 1). Ideally, these defects should be closed in infancy, and the transpulmonary approach is recommended to achieve closure. In the first group, there was one death in a patient with a hypoplastic right ventricle. In Group 2, nineteen patients had aortic valve prolapse or aortic valve regurgitation. The DCVSD were moderately large or small. A number of DCVSD in Group 2 patients had maintained the normal offsetting of the arterial valves. These defects must be closed by the time mild aortic valve regurgitation has occurred. In Group 2, there was one late death in a patient who developed subacute bacterial endocarditis. The two patients who had severe aortic valve regurgitation required aortic valve replacement and underwent multiple surgical procedures to replace calcified bioprostheses. Group 3 comprised 13 patients who were diagnosed with tetralogy of Fallot. All of these patients had a large DCVSD with aortic valve overriding. All Group 3 patients survived radical repair of the defect, which required a transannular patch in most cases (76%).

Entities:  

Mesh:

Year:  1988        PMID: 3180405

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

1.  Correlation of anatomic and hemodynamic features with aortic valve leaflet deformity in doubly committed subarterial ventricular septal defect.

Authors:  J Kobayashi; K Koike; H Senzaki; T Kobayashi; M Tsunemoto; A Ishizawa; Y Ohta; M Shimada; R Omoto
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

2.  Measurement of Aortic Valve Coaptation and Effective Height Using Echocardiography in Patients with Ventricular Septal Defects and Aortic Valve Prolapse.

Authors:  Satoru Iwashima; Hiroki Uchiyama; Takamichi Ishikawa; Kiyohiro Takigiku; Ken Takahashi; Manatomo Toyono; Nao Inoue; Masaki Nii
Journal:  Pediatr Cardiol       Date:  2017-01-21       Impact factor: 1.655

3.  Conal Septal Hypoplasia in Tetralogy of Fallot-Impact on Clinical Course, Treatment Strategies, and Outcomes After Surgical Intervention.

Authors:  Kirsten E Borsheim; Ronald K Woods; Evelyn M Kuhn; Peter C Frommelt
Journal:  Pediatr Cardiol       Date:  2022-07-19       Impact factor: 1.838

4.  The natural history and timing of the radical operation for subpulmonic ventricular septal defects.

Authors:  T Anzai; T Iijima; I Yoshida; Y Sakata; T Obayashi; S Ishikawa
Journal:  Jpn J Surg       Date:  1991-09

5.  Ventricular septal defects: morphology of the doubly committed juxtaarterial and muscular variants.

Authors:  K McCarthy; S Ho; R Anderson
Journal:  Images Paediatr Cardiol       Date:  2000-07

6.  Minimally invasive perventricular device closure of doubly committed sub-arterial ventricular septal defects: single center long-term follow-up results.

Authors:  Shu Zhang; Da Zhu; Qi An; Hong Tang; Dajiang Li; Ke Lin
Journal:  J Cardiothorac Surg       Date:  2015-09-15       Impact factor: 1.637

7.  Tetralogy of Fallot with subarterial ventricular septal defect: Surgical outcome in the current era.

Authors:  Vimalarani Devendran; Prakash R Anjith; Anil Kumar Singhi; Vimala Jesudian; Ejaz Ahmed Sheriff; Kothandam Sivakumar; Roy Varghese
Journal:  Ann Pediatr Cardiol       Date:  2015 Jan-Apr

8.  Doubly committed Subarterial Ventricular Septal defect repair: An experience of 51 cases.

Authors:  Tariq Waqar; Muhammad Farhan Ali Rizvi; Ahmad Raza Baig
Journal:  Pak J Med Sci       Date:  2017 Sep-Oct       Impact factor: 1.088

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.